Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats.

McAlister KW, Scholpa NE, Janda J, Schnellmann RG.

Open source

DOI
10.1016/j.bcp.2026.118482
Published
2026-09-16
Container
Biochem Pharmacol
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bcp.2026.118482,
  title = {Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats.},
  author = {McAlister KW and  Scholpa NE and  Janda J and  Schnellmann RG.},
  year = {2026},
  journal = {Biochem Pharmacol},
  doi = {10.1016/j.bcp.2026.118482},
  url = {https://doi.org/10.1016/j.bcp.2026.118482}
}

RIS

TY  - JOUR
TI  - Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats.
AU  - McAlister KW
AU  -  Scholpa NE
AU  -  Janda J
AU  -  Schnellmann RG.
PY  - 2026
JO  - Biochem Pharmacol
DO  - 10.1016/j.bcp.2026.118482
UR  - https://doi.org/10.1016/j.bcp.2026.118482
ER  - 

APA

KW, M., NE, S., J, J., & RG., S. (2026). Pharmacological antagonism of HTR2B reduces ERK and STAT3 activation and prevents renal fibrosis during the development of Adenine-Induced CKD in rats.. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2026.118482

Source records